Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488538 | 0.94 | BTK (0.50) | BTKUSP30IDH1ALDH1A1MAPT | |
| SCHEMBL25302816 | 0.94 | BTK (0.50) | BTKUSP30IDH1ALDH1A1MAPT | |
| SCHEMBL29326041 | 0.94 | BTK (0.50) | BTKUSP30IDH1ALDH1A1MAPT | |
| SCHEMBL25302818 | 0.94 | BTK (0.50) | BTKUSP30IDH1ALDH1A1MAPT | |
| SCHEMBL31341798 | 0.86 | CDK4 (0.39) | BTKUSP30IDH1ALDH1A1NPC1 | |
| SCHEMBL29325933 | 0.86 | CDK4 (0.46) | BTKUSP30IDH1ALDH1A1NPC1 | |
| SCHEMBL30053983 | 0.85 | BTK (0.37) | BTKUSP30IDH1ALDH1A1NPC1 | |
| SCHEMBL23292333 | 0.83 | CDK12 (0.56) | BTKUSP30IDH1ALDH1A1NPC1 | |
| SCHEMBL22895770 | 0.83 | CDK12 (0.56) | BTKUSP30IDH1ALDH1A1NPC1 | |
| SCHEMBL28544916 | 0.83 | CDK12 (0.56) | BTKUSP30IDH1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | BTK 2826/4885USP30 1220/4885IDH1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.